Starpharma advances leading cancer therapeutic in drug delivery program

Starpharma today announced the nomination of leading anti-cancer drug docetaxel as a lead candidate in its cancer drug delivery program following encouraging early results.

  • Starpharma’s dendrimers demonstrate improvements in multibillion dollar chemotherapy drug, docetaxel;
  • Water solubility improved more than 2000-fold, potentially reducing serious side effects;
  • Starpharma to advance a dendrimer-docetaxel formulation as a lead candidate in its drug delivery cancer program.

Audio Broadcast - BV Efficacy Trial Results

Starpharma invites you to listen to an audio broadcast with Chief Executive Officer Dr Jackie Fairley, regarding the successful results of the major phase 2 clinical study that demonstrated efficacy of VivaGel® for the treatment of bacterial vaginosis (BV).

To listen to the Boardroom Radio audio broadcast please click here

VivaGel® Demonstrates Efficacy in Bacterial Vaginosis

Starpharma today announced successful results of a major phase 2 clinical study that demonstrated efficacy of VivaGel® for the treatment of bacterial vaginosis (BV).

 Key Points:

  •  VivaGel® meets primary endpoint, demonstrating significant efficacy for treatment of BV
  • VivaGel® expected to avoid many shortcomings of existing therapies

VivaGel® Coated Condom: Licence Agreement for Japan with Okamoto

Starpharma today announced that it has signed a licence agreement with Okamoto Industries Inc  in relation to the VivaGel®-coated condom for the Japanese market.  Okamoto is the market leader for condoms sold in Japan, the world’s second largest condom market.

Quarterly Cashflow Report - March 2011

The cash balance at 31 March 2011 was $20.1m compared to $19.7m at 31 December 2010.

 

The Operating & Investing cash outflow of $1.6m for the quarter includes the costs of the fully enrolled phase 2 study assessing VivaGel® as a treatment for bacterial vaginosis. Financing cash inflows of $2.0m included proceeds from the exercise of share options during the quarter.

 

Shareholder Update March 2011

 

In this issue:

› Enrolment completed for Phase2 study of VivaGel® for treatment of BV

› Strengthening shareholderbase – new domestic and European investors

› Broad appeal of SPL’sdendrimer technology platform – agrochemicals and drug delivery

› Starpharma’s performance vs the market

 

Download: Shareholder Update: March 2011 ( pdf file, 530kb)


Completes Enrolment for Phase 2 Study of VivaGel for Treatment of BV

Starpharma today announced it had completed enrolment and all patient follow-up visits in its phase 2 study of VivaGel® for the treatment of bacterial vaginosis (BV).

This study investigated the effectiveness of VivaGel® administered once daily for seven days in the treatment of BV and enrolled 132 participants in the US. Data is now being processed and results will be available in the second quarter of this year.

Starpharma presents at ASX Emerging Growth Conference, London

Starpharma is today presenting at the ASX Emerging Growth conference in London. 

More than 150 institutional fund managers are confirmed for the event.  Starpharma is one of 18 companies participating in this invitation only event, and one of only two healthcare companies. Mesoblast is the other.  

 

Presentation: SPL presents at ASX Emerging Growth Conference ( pdf file, 2MB)

Starpharma to expand agricultural program through $250,000 funding

Starpharma has been awarded $250,000 funding to enhance agrochemicals using its Priostar® dendrimers. The funding as part of the Victorian Government’s Small Technologies Industry Uptake Program (STIUP), will allow Starpharma to expand its Melbourne-based agricultural programs, further enhancing the commercial prospects of promising candidates. 

Starpharma interim report and half-year financial results

Starpharma released its interim report and financial results for the half-year ended 31 December 2010.

 

Financial Results

  • Cash position at 31 December 2010 $19.7M
  • Net cash burn for the half-year $3.1M
  • Operating cash outflows for the half-year $3.75M
  • Reported loss $4.2M.

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.